A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

A Double-Blind, Multicenter, Placebo-Controlled Study of MK0777 Gel Extrusion Module (GEM) 1.5 mg b.i.d. in the Treatment of Outpatients With Generalized Anxiety Disorder

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00703833

Enrollment

Registered

2008-06-24

Start date

2002-09-30

Completion date

2003-02-28

Last updated

2015-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Brief summary

The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.

Interventions

DRUGMK0777

Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777

DRUGPlacebo (unspecified)

matching placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Male or Female * Current diagnosis of Generalized Anxiety Disorder * Age 18 - 70

Exclusion criteria

* Women who are pregnant, or breast-feeding * Use of illicit drugs * History of drug or alcohol dependence

Design outcomes

Primary

Measure	Time frame
Measure the reduction of anxiety	after 4 weeks and at end of study

Secondary

Measure	Time frame
Safety and efficacy	throughout study and at end of study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026